Ozempic 0.25 mg solution for injection in pre-filled pen

The safety and efficacy of acute subcutaneous administration of semaglutide in non-diabetic patients with acute ischemic stroke: a multicentre, phase 2, prospective, randomized, open-label, blinded endpoint trial (ASSET)

Semaglutide Treatment for Prevention of Toxicity in High-dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation – a randomized, double-blind, placebo-controlled, investigator-initiated study

A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity (SWIFT Study)

The SEMAFOOT2 Pilot. Effect of semaglutide on healing of foot ulcers in type 2 diabetes patients. A Pilot study.

An open-label, single-center, non-controlled pilot clinical trial to assess the efficacy of weekly semaglutide in combination with regular counselling sessions to reduce craving and use of chemsex associated drugs (CoSem4Chemsex) study.

A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease.

Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes

TOLEDDO: Effect of weekly GLP1 agonist treatment in "double diabetes": a randomized, open-label study

Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.

Screening and intervention for subclinical coronary artery disease in patients with type 2 diabetes: THE STENO INTEN-CT STUDY

Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

Semaglutide and Finerenone for Kidney and Vascular Protection in CKD

Healing Diabetic Foot Ulcers with Semaglutide